celecoxib Articles
Canadian Medical Assoc slams regulators over approvals
10 January 2005
Stock Commentary - New York
10 January 2005
Editor's views on "Big Pharma" in 2004
10 January 2005
NIH: no higher CV risk seen in ADAPT study with Celebrex
10 January 2005
Bayer and Stada hit by FDA warning on naproxen
10 January 2005
Pfizer setback with Celebrek trial
10 January 2005
German post-Vioxx warning on COX-2s
20 December 2004
Yamanouchi overcomes drug pric cuts
22 November 2004
Vioxx different to other COX-2s; study
22 November 2004
Pfizer defends Celebrex safety
15 November 2004
Vioxx withdrawal will not hurt COX-2s initially, says NOP survey
8 November 2004
EMA to review COX-2 inhibitors
1 November 2004
Stock Commentary - New York
25 October 2004
US Sen questions Merck on FDA/Vioxx pact
25 October 2004
Tokyo pharma stocks - week to October 4
11 October 2004
Arthritis Rx ads "reach up to 75% of US patients"
4 October 2004
Vioxx study indicates heart risks
6 September 2004
Tokyo pharma stocks - week to June 14
14 June 2004
Yamanouchi deal with Pfizer restructured
7 June 2004
Weak core products sales at Yamanouchi
31 May 2004
6M Americans have bought drugs on-line
29 March 2004
US court dismisses Univ of Rochester Celebrex patent case
23 February 2004
US DTC ad spend, and response, levels off
20 October 2003
US FDA seizes "potentially dangerous" drugs from repackager
22 September 2003
Novartis' Prexige benefits OA patients
30 June 2003
Novartis' Prexige benefits OA patients
30 June 2003
New study shows companies' licensing successes
30 June 2003
Yamanouchi's FY2003 operating income up 12%
26 May 2003
Celebrex GI safety study
26 May 2003
Pfizer gets Euro OK for COX-2 blocker Bextra
26 May 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
ProEthic transdermal ketoprofen deal
14 April 2003
Canadian pharmacy to open 360 US units
31 March 2003
MisRxing "could cost Australia A$1B/year"
17 March 2003
First launch, in Canada, for AstraZeneca's superstatin Crestor
24 February 2003
S&P confirms Pfizer's AAA credit rating
24 February 2003
Update: Pharmacia's earnings match forecasts in 2002
24 February 2003
Pharmacia's earnings match forecasts in 2002
24 February 2003
New York Stock Commentary - 2 weeks to Dec 30
6 January 2003
Celebrex as good as two drugs for ulcers
6 January 2003
Tokyo pharma stocks - 2 weeks to Dec 30
6 January 2003
Pharmacia, Yamanouchi file celecoxib in Japan
6 January 2003
Australian Pharma sales up 15%
5 August 2002
10 most effective US DTC television ads
5 August 2002
Pharmacia/Pfizer welcome CPMP move
5 August 2002
Pharmacia EPS up by 8% in 2nd-quarter
29 July 2002
Pfizer's 2nd-qtr net income rises 10%
22 July 2002
Stock Commentary - New York
17 June 2002
FDA clears Celebrex label change
17 June 2002
Yamanouchi expects YM175 OK this year
3 June 2002
Brand name confusion "a risk for patients"
27 May 2002
Pharmacia sales take a dip in first quarter
29 April 2002
Pfizer 1st-qtr EPS increases 18%
22 April 2002
France's top-selling Rx drugs in 2001
15 April 2002
US insurers requiring prior OK for COX-2s
25 March 2002
Merck & Co claims victory in COX-2 patent dispute
11 March 2002
UK NICE guidance on COX-2s "may be short-sighted"
25 February 2002
Bextra is opioid-sparing in knee surgery
18 February 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
NICE "should appraise innovative new drugs a year before launch"
4 February 2002
Pharmacia's product pipeline; what's in store after Celebrex?
29 November 2001
Update: Pharmacia gets US approval for Celebrex follow-up Bextra
20 November 2001
Pharmacia's second COX-2 cleared by FDA
19 November 2001
Pharmacia EPS rises 24% in third quarter
24 October 2001
Celebrex approved for pain indication in USA
24 October 2001
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
